Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HALOZYME THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HALOZYME THERAPEUTICS's regulatory disclosures and financial reporting.
Halozyme Therapeutics, Inc. is registering 219,336 shares of its common stock, par value $0.001 per share, for issuance upon exercise of stock options outstanding under the Elektrofi, Inc. 2015 Equity Incentive Plan, as amended. These options were assumed in connection with Halozyme’s acquisition of Elektrofi, Inc., which closed pursuant to a merger in which Elektrofi became a wholly owned subsidiary of Halozyme. The filing also confirms that Halozyme has incorporated a broad set of previously filed reports and describes its standard Delaware-law indemnification protections for directors and officers, including charter and bylaw provisions, individual indemnification agreements, and related insurance coverage.
Halozyme Therapeutics (HALO) insider activity: The President and CEO, who also serves as a director, exercised stock options and sold shares under a Rule 10b5-1 trading plan adopted on March 21, 2025.
Across November 10–12, 2025, the executive exercised 60,000 options at $8.11 per share (20,000 each day) and sold 60,000 shares in multiple tranches. Reported weighted average sales prices included $68.714 and $69.3 on November 10; $67.892, $68.795, and $69.731 on November 11; and $70.218, $71.089, and $71.667 on November 12. The sales reflect shares acquired from option exercises, with the underlying options having a ten‑year term expiring in February 2026.
Following the reported transactions, the executive beneficially owned 733,719 shares directly. Remaining options beneficially owned declined to 16,569 after these exercises.
Halozyme Therapeutics (HALO) reported an insider transaction by a director. On 11/10/2025, the director sold 2,000 shares of common stock at $68.48 per share under a Rule 10b5-1 trading plan adopted on May 29, 2025. Following the sale, the director beneficially owns 42,952 shares, held directly.
Halozyme Therapeutics completed a $1.5 billion convertible note financing, split between $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million of 0.875% Convertible Senior Notes due 2032, including full exercise of the Initial Purchasers’ options.
The company received net proceeds of approximately $1.47 billion. It used about $182.7 million for capped call transactions and paid approximately $1.020 billion in cash to repurchase portions of its 2027 and 2028 convertible notes. The remaining proceeds are earmarked for general corporate purposes, potential acquisitions and strategic transactions, and potential future note repurchases or repayment at maturity.
The notes are convertible at an initial rate of 11.4683 shares per $1,000 (conversion price ~$87.20). The 2032 notes bear 0.875% interest, paid semi‑annually starting May 15, 2026; the 2031 notes bear no regular interest. Capped calls carry an initial cap price of $136.78 per share. Holders have customary conversion windows and protections, including Fundamental Change repurchase rights and Make‑Whole adjustments, under the new indentures.
Halozyme Therapeutics announced the pricing of two convertible senior note offerings to institutional investors under Rule 144A. The company plans to issue $650.0 million aggregate principal amount of notes due 2031 and $650.0 million due 2032. Initial purchasers received a 13-day option to buy up to an additional $100.0 million of each series. The notes are being offered only to persons reasonably believed to be qualified institutional buyers.
A press release with additional details was furnished as Exhibit 99.1.
Halozyme Therapeutics (HALO) amended its credit facility, extending and upsizing its revolving line to $750,000,000. The amended revolver now matures on the earlier of November 5, 2030 or a springing maturity date, with borrowings priced at Term SOFR or a base rate plus an applicable margin ranging from 0.25% to 1.25% for base rate loans and 1.25% to 2.25% for Term SOFR loans. As of November 5, 2025, outstanding borrowings were $0.
The company also announced proposed convertible offerings: $650.0 million aggregate principal amount of notes due 2031 and $650.0 million due 2032, with an expected 13‑day option for initial purchasers to buy up to an additional $100.0 million of each series. The credit agreement includes customary covenants, including a maximum consolidated net leverage ratio of 4.50 to 1.00 (temporarily increasing by 0.50 after a material acquisition) and a minimum consolidated interest coverage ratio of 3.00 to 1.00.
Halozyme Therapeutics (HALO) reported stronger quarterly results. For the three months ended September 30, 2025, total revenues were $354,264,000 versus $290,084,000 a year ago, driven by royalties of $236,038,000 and product sales of $94,228,000. Net income was $175,225,000 compared to $137,011,000, with diluted EPS of $1.43 versus $1.05.
For the nine months, revenue reached $944,844,000 versus $717,316,000, and net income was $458,480,000 versus $307,079,000, reflecting broad growth in royalties and milestones. Operating cash flow was $432,529,000, supporting cash and cash equivalents of $419,665,000 at quarter end.
The company repurchased common stock using $342,372,000 year-to-date. On the balance sheet, current portion of long-term debt, net, was $710,685,000 and long-term debt, net, was $800,072,000. Shares outstanding were 117,597,000 as of October 27, 2025. Stockholders’ equity increased to $503,915,000 from $363,821,000 at December 31, 2024.
Halozyme Therapeutics, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 under Item 2.02.
The company also disclosed a planned CFO transition. Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue as CFO until the earlier of when a new CFO is hired or March 30, 2026, after which she will depart to pursue a new professional opportunity. Halozyme has initiated a search for its next CFO.
The company stated that Ms. LaBrosse’s departure is not due to any disagreement with its independent auditors or with the company regarding financial statements, internal control over financial reporting, operations, policies, or practices. The company expects to enter into a transition and release agreement with Ms. LaBrosse.
Halozyme Therapeutics (HALO) furnished a Regulation FD update announcing it issued a statement on the final IPAY 2028 guidance for Medicare price negotiations from the U.S. Centers for Medicare & Medicaid Services. The statement includes the company’s long‑term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE partner product subcutaneous sales. The statement is available on the company’s website and attached as Exhibit 99.1. This information is furnished under Item 7.01 and is not deemed filed or incorporated by reference.
Officer equity grants and option exercise reported. The reporting person, Cortney Caudill, SVP and Chief Operating Officer, acquired 9,031 shares via an option exercise with an exercise price of $68.98 and was granted 3,625 restricted stock units (RSUs). The option vests 25% on 10/03/2026 then monthly thereafter over the remaining term to 10/03/2035. The RSU award vests 25% on the first anniversary and then in annual 25% installments thereafter. Following these transactions, the reporting person beneficially owns 9,031 option-derived shares and 3,625 RSUs, reported as direct ownership.